SLP Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
49 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 52.91
- PEG ratio
- 9.88
- P/B
- 2.65
- P/S (TTM)
- 4.49
- EV/EBITDA
- 18.66
Profitability & growth
- ROE (TTM)
- 6.2%
- Operating margin
- 22.8%
- Revenue growth YoY
- 7.5%
- Dividend yield
- —
- Beta
- 1.31
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Simulations Plus Inc
Company profileSimulations Plus, Inc. develops drug discovery and development software for mechanistic modeling, simulation, and prediction of molecule properties using artificial intelligence and machine learning technology worldwide. The company is headquartered in Lancaster, California.
Classification
- Sector
- Healthcare
- Industry
- Health Information Services
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 800 PARK OFFICES DRIVE, RESEARCH TRIANGLE PARK, NC
- Fiscal year end
- August
- Latest quarter
- May 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
